SEC Form 4 · accession 0001193125-26-292767
Monte Rosa Therapeutics, Inc. · GLUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Filip Janku
Officer — Chief Medical Officer
Period of report
Jun 30, 2026
Accepted (ET)
Jul 1, 2026 · 4:57 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001826457
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 30, 2026 | M | 5,407 | $13.41 | A | 66,019 | D | |
| Common Stock | Jun 30, 2026 | S | 5,407 | $24.50 | D | 60,612 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $13.41 | Jun 30, 2026 | M | 5,407 | D | — | Feb 29, 2032 | Common Stock | 5,407 | 81,093 | D |
Explanation of responses
- F1These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026.
- F2Includes 620 shares acquired under the Issuer's 2021 Employee Stock Purchase Program on June 30, 2026.
- F3The shares underlying this option are fully vested and exercisable.